News AbbVie axes multi-billion cancer flop Rova-T after another t... AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.
News Roche under pressure in US as Amgen/Allergan launch US cance... Amgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the US.
News NICE recommends funding for psoriasis and type 1 diabetes dr... Patients in England and Wales should soon be able to access AbbVie’s psoriasis drug Skyrizi after NICE recommended regular NHS funding.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
